Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lotus Pharmaceutical Registers Increased Q1 Growth; Will Pursue Acquisitions, Product Diversification

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Beijing-based Lotus Pharmaceuticals will further diversify its product portfolio and make acquisitions in the long term, the company said at the back of announcing increased growth figures over the first quarter ended March 31
Advertisement

Related Content

Chinese Regulators Provide Fast-track Review Status For Lotus On Modified Version Of AstraZeneca's Bambec
Chinese Regulators Provide Fast-track Review Status For Lotus On Modified Version Of AstraZeneca's Bambec
Lotus Set To Build New Manufacturing Facility, Pharma Park In Inner Mongolia
Lotus Set To Build New Manufacturing Facility, Pharma Park In Inner Mongolia
Advertisement
UsernamePublicRestriction

Register

SC068591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel